Ethan S. Burstein

5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics

David M. Weiner, Ethan S. Burstein, N. T. Nash et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 201 citations

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Kimberly E. Vanover, David M. Weiner, Malath Makhay et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 196 citations · Full text

Discovery of an Ectopic Activation Site on the M₁Muscarinic Receptor

Tracy A. Spalding, Carol Trotter, Niels Skjærbæk et al. · Molecular Pharmacology · 2002 · 187 citations

Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist

Ethan S. Burstein, Jin Ma, Steven Wong et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 181 citations · Full text

Trazodone kinetics: Effect of age, gender, and obesity

David J. Greenblatt, H. Friedman, Ethan S. Burstein et al. · Clinical Pharmacology & Therapeutics · 1987 · 127 citations

Obesity, Trazodone Kinetics, Aging +12